Despite this limitation, Rh2 has demonstrated significant pharmacological activity in various in vitro models, and in vivo studies have reported promising outcomes, such as reduced tumor incidence in mice following oral administration [46,47]. The gene discussed is RHAG; the disease is neoplasm.